NEU have a licensing and royalties agreement with Acadia...

NEU have a licensing and royalties agreement with Acadia pharmaceuticals; under this agreement Acadia gained FDA approval for Daybue which is a treatment for Rhett’s syndrome, this gained a PRV (priority review voucher) which can be onsold and is valued at $100m.
This now has me thinking as to what business strategies IMU now has for it’s own pipeline of products, I think clarification needs to be forthcoming with our new alliance and whether their may be eligibility’s for PRV’s if we take things through all the way, we will have manufacturing capabilities in future by the sound of things.